Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.4061/2011/873548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564757211643904 |
|---|---|
| author | Kawin Leelawat Siriluck Narong Jerasak Wannaprasert Surang Leelawat |
| author_facet | Kawin Leelawat Siriluck Narong Jerasak Wannaprasert Surang Leelawat |
| author_sort | Kawin Leelawat |
| collection | DOAJ |
| description | Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients.
Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and 50 benign biliary tract disease cases were randomly selected from a cohort of consecutive cases of biliary tract diseases. Their sera were measured for the levels of NGAL and the widely used serum cholangiocarcinoma marker, carbohydrate antigen 19-9 (CA19-9).
Results. The serum CA19-9 and NGAL levels were significantly elevated in cholangiocarcinoma patients (CA19-9: 𝑃<.001, NGAL: 𝑃<.001). The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma of CA19-9 and NGAL was 0.81 and 0.79, respectively.
Conclusion. The diagnostic accuracy of serum NGAL and CA19-9 makes them good candidates for use as biomarkers to discriminate cholangiocarcinoma patients from benign biliary tract disease patients. |
| format | Article |
| id | doaj-art-73648b7b4d6a4d1eb744e0c4eee5a87d |
| institution | Kabale University |
| issn | 2090-3448 2090-3456 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj-art-73648b7b4d6a4d1eb744e0c4eee5a87d2025-02-03T01:10:16ZengWileyInternational Journal of Hepatology2090-34482090-34562011-01-01201110.4061/2011/873548873548Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract DiseasesKawin Leelawat0Siriluck Narong1Jerasak Wannaprasert2Surang Leelawat3Department of Surgery, Rajavithi Hospital, Bangkok 10400, ThailandDepartment of Surgery, Rajavithi Hospital, Bangkok 10400, ThailandDepartment of Surgery, Rajavithi Hospital, Bangkok 10400, ThailandFaculty of Pharmacy, Rangsit University, Pathumthani 12000, ThailandAim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and 50 benign biliary tract disease cases were randomly selected from a cohort of consecutive cases of biliary tract diseases. Their sera were measured for the levels of NGAL and the widely used serum cholangiocarcinoma marker, carbohydrate antigen 19-9 (CA19-9). Results. The serum CA19-9 and NGAL levels were significantly elevated in cholangiocarcinoma patients (CA19-9: 𝑃<.001, NGAL: 𝑃<.001). The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma of CA19-9 and NGAL was 0.81 and 0.79, respectively. Conclusion. The diagnostic accuracy of serum NGAL and CA19-9 makes them good candidates for use as biomarkers to discriminate cholangiocarcinoma patients from benign biliary tract disease patients.http://dx.doi.org/10.4061/2011/873548 |
| spellingShingle | Kawin Leelawat Siriluck Narong Jerasak Wannaprasert Surang Leelawat Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases International Journal of Hepatology |
| title | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| title_full | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| title_fullStr | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| title_full_unstemmed | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| title_short | Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases |
| title_sort | serum ngal to clinically distinguish cholangiocarcinoma from benign biliary tract diseases |
| url | http://dx.doi.org/10.4061/2011/873548 |
| work_keys_str_mv | AT kawinleelawat serumngaltoclinicallydistinguishcholangiocarcinomafrombenignbiliarytractdiseases AT sirilucknarong serumngaltoclinicallydistinguishcholangiocarcinomafrombenignbiliarytractdiseases AT jerasakwannaprasert serumngaltoclinicallydistinguishcholangiocarcinomafrombenignbiliarytractdiseases AT surangleelawat serumngaltoclinicallydistinguishcholangiocarcinomafrombenignbiliarytractdiseases |